News - Abzena

Filter by year

Filter by topic

Novel antibodies against a ground-breaking new target for the treatment of Cardiovascular Fibrosis developed by Enleofen Bio, with support from Abzena, featured in ‘Nature’ article

Cambridge, UK and Singapore, 14 November 2017 Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio Pte Ltd (‘Enleofen Bio’), to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases. The Founders of Enleofen Bio discovered […] Read more

Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

CAMBRIDGE, England & HENNIGSDORF, Germany- Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sclerosis (MS). […] Read more

Abzena begins the installation of a new 500 L bioreactor at its San Diego facility

Abzena have begun the installation of a new 500L BIOSTAT® STR, single-use bioreactor, as part of a series of significant investments in its San Diego process development and manufacturing operations. This expansion is in response to a general demand in the marketplace and the need of current clients with clinical successes for larger volume production […] Read more

Abzena appoints Lotta Ljungqvist as Non-Executive Director

Cambridge, UK, 19 September 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company. Lotta Ljungqvist has a broad range of commercial and directorial experience. […] Read more

Trading Update

Cambridge, UK, 14 September 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, announces a trading update for the period to 14 September 2017, ahead of its AGM being held at 10am today at the Babraham Research Campus. Revenues for […] Read more

Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Telix to develop products for imaging and treatment of prostate cancer Cambridge, UK and Melbourne, Australia 18 July 2017 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Telix Pharmaceuticals Limited (‘Telix’), a biopharmaceutical company […] Read more

Abzena and OBI Pharma sign ThioBridge™ licence agreement

– Master Services and Clinical Supply agreement to enable process development and manufacturing by Abzena Cambridge, UK, Taipei, Taiwan, 11 July 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement and a master services […] Read more

Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues

Cambridge, UK, 13 June 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017. Corporate highlights Integration of Abzena’s service offering for biopharmaceutical development and manufacturing […] Read more

Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009

Cambridge, UK, 24 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes the announcement from Bioverativ Inc. (NASDAQ: BIVV), that it has entered into a definitive agreement to acquire True North Therapeutics for an upfront payment of […] Read more

Notice of full year results

Cambridge, UK, 16 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full year results for the year to 31 March 2017 on Tuesday, 13 June 2017. A presentation for analysts will be held […] Read more

Interested in our services? Get In Touch